Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03770689 · ClinicalTrials.gov registry record · Phase 1
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT03770689 is a Phase 1 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 19 participants.
The verdict
NCT03770689, a Phase 1 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
The main purpose of the study was to define maximum tolerated dose (MTD), recommended Phase II dose (RP2D) safety and tolerability of Peposertib in combination with capecitabine and radiotherapy (RT).
Interventions
- DRUG Capecitabine
- DRUG Peposertib 50 mg
- DRUG Peposertib 100 mg
- DRUG Peposertib 150 mg
- DRUG Peposertib 250 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2019-03-20 |
| Est. Completion | 2022-02-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03770689
The ClinicalTrials.gov registry entry for NCT03770689 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Capecitabine is the first listed.
NCT03770689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03770689 about?
NCT03770689 is a clinical study titled "Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer". The main purpose of the study was to define maximum tolerated dose (MTD), recommended Phase II dose (RP2D) safety and tolerability of Peposertib in combination with capecitabine and radiotherapy (RT).
What is the current status of trial NCT03770689?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-03-20. Estimated completion is 2022-02-21.
What interventions are being tested in trial NCT03770689?
The interventions under investigation include: Capecitabine (DRUG), Peposertib 50 mg (DRUG), Peposertib 100 mg (DRUG), Peposertib 150 mg (DRUG), Peposertib 250 mg (DRUG).
Who is sponsoring clinical trial NCT03770689?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.